Multiple Dose Safety Study of SRX246 Capsules in Healthy Volunteers (AVN007)
This study has been completed.
Information provided by:
First received: March 15, 2010
Last updated: July 17, 2010
Last verified: July 2010
This is a multiple dose clinical study to be conducted with SRX246 capsules to determine the safety, tolerability and pharmacokinetics of the drug over a 14 day dosing period.
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
||Phase I, Double-Blind, Placebo-Controlled, Ascending, Multiple-Dose, Safety, Tolerability and Pharmacokinetic Study of SRX246 Capsules in Healthy Adult Volunteers
Primary Outcome Measures:
- Safety will be determined by performing vital sign measurements, ECGs, complete physical examinations, hematology and clinical chemistry tests, and recording of any reported adverse experiences. [ Time Frame: 14 days ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Pharmacokinetics of SRX246 will be determined by taking periodic blood samples for measurement of SRX246 levels. [ Time Frame: 14 days ] [ Designated as safety issue: No ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||June 2010 (Final data collection date for primary outcome measure)
Placebo Comparator: Placebo
This study is intended to evaluate the safety, tolerability and pharmacokinetic profile of multiple oral doses of SRX246 in healthy adult volunteers.
|Ages Eligible for Study:
||18 Years to 55 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Males and non-pregnant, non-lactating females of non-childbearing potential. Female patients should be either post-menopausal or surgically sterile.
- Age ≥18 and ≤55 years.
- Body mass index (BMI) of 18.5 to 34.0 kg/m2, inclusive, and a total body weight of >50kg (110 pounds).
- In good health as determined by medical history, a baseline physical examination, vital signs, clinical laboratory tests and electrocardiogram (ECG) measurement.
- Subject is willing and able to sign written informed consent prior to receipt of any study medication or beginning study procedures.
- Subject is willing and able to follow instructions, comply with the protocol requirements and make all required study visits.
- Pregnant or lactating females, or females of childbearing potential.
- Subject is positive for HIV, hepatitis B surface antigen or hepatitis C antibody tests at screening.
- Subject with a positive urine test for drugs of abuse or alcohol at screening or at admission to the clinic on study Day -1.
- Evidence of any out-of range laboratory value at screening that has not been reviewed, approved and documented as not clinically significant by the Principal Investigator.
- Subject who has resting supine blood pressure outside of a systolic blood pressure range of 90-140 mmHg or a diastolic blood pressure outside a range of 50-90 mmHg on two consecutive measurements taken up to 10 minutes apart.
- Subject who has resting supine pulse rate greater than 100 bpm or less than 50 bpm on two consecutive measurements taken up to 10 minutes apart.
- Subject has taken any alcohol within 48 hours of ANY study-related activities AND cannot abstain from drinking alcohol during the entire duration of the subject's study participation.
- Subject has used any tobacco products in the past 12 months.
- A history of significant drug allergy or systemic allergic disease (e.g., urticaria, atopic dermatitis).
- A general medical or psychological condition or behavior, including current substance dependence or abuse that, in the opinion of the investigator, might not permit the subject to complete the study or sign the informed consent.
- Any clinically significant abnormality on screening resting 12-lead ECG (e.g., heart block, conduction disorders, ventricular and/or atrial arrhythmias).
- Any other condition or clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening that, in the opinion of the Principal Investigator or the Physician Sub-Investigator, would make the subject unsuitable for the study or put them at additional risk.
- Routine or PRN consumption of medications or herbal supplements that the subject is unable or unwilling to discontinue during the study.
- Inability to understand or follow study instructions.
- Treatment with an investigational drug within 30 days preceding the first dose of study medication.
- Known allergy or hypersensitivity to the investigational study drug/placebo components.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01088932
|SNBL Clinical Pharmacology Center
|Baltimore, Maryland, United States, 21201 |
||Stephan A Bart, MD
||SNBL Clinical Pharmacology Center
No publications provided
||Neal G. Simon, PhD, Azevan Pharmaceuticals, Inc.
History of Changes
|Other Study ID Numbers:
|Study First Received:
||March 15, 2010
||July 17, 2010
||United States: Food and Drug Administration
Keywords provided by Azevan Pharmaceuticals:
ClinicalTrials.gov processed this record on December 04, 2013
Safety in Healthy Volunteers